Synthesis and characterization of a novel Naphthalimide-Selenium based Temozolomide drug conjugate in glioma cells
- 26 November 2024
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 154, 107998
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Design, synthesis and biological evaluation of 3-nitro-1,8-naphthalimides as potential antitumor agentsBioorganic & Medicinal Chemistry Letters, 2020
- Selenium Enhances the Apoptotic Efficacy of Docetaxel Through Activation of TRPM2 Channel in DBTRG Glioblastoma CellsNeurotoxicity Research, 2019
- Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck CancersCell Reports, 2018
- Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell LinesNeurochemical Research, 2016
- Detoxification of oxidative stress in glioma stem cells: Mechanism, clinical relevance, and therapeutic developmentJournal of Neuroscience Research, 2014
- Selenium-containing naphthalimides as anticancer agents: Design, synthesis and bioactivityBioorganic & Medicinal Chemistry, 2012
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- DNA repair and cancer stem-like cells – Potential partners in glioma drug resistance?Cancer Treatment Reviews, 2008
- Reactive oxygen species in cancer cells: Live by the sword, die by the swordCancer Cell, 2006
- Phase I study of mitonafide in solid tumorsInvestigational New Drugs, 1992